{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:15Z","timestamp":1791942855581,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive form of pulmonary hypertension in which increased arterial pressure causes remodeling of the arterial system and is associated with heart failure. Methamphetamine is a stimulant that has recently become a focus in PAH research, but the recent trends and demographics of this cohort of patients are not known. The study aimed to analyze the overall trends and demographics of PAH patients with and without concurrent methamphetamine usage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study used the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality (AHRQ) from 2008 to 2020 to calculate nationally weighted estimates for both conditions by ICD-9 and ICD-10 diagnosis codes. We used several statistical measures, including descriptive statistics with design-based chi-square and <jats:italic>t<\/jats:italic>-tests, trend analysis with Cochran-Armitage test, generalized linear models, and other data preprocessing measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold). Most of the hospitalized patients were males (59.16%), aged 41\u201364 (45.77%), White (68.64%), from the West (53.09%), with Medicaid (50.48%), and with median income &amp;lt;$25,000. The rate of increase over the period was higher for males (11.8-fold), race (not sure which race; please check and modify), aged 41\u201364 (11.3-fold), and in the South (15.1-fold). An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI\u2009=\u200931.19\u201333.22) compared to non-users. With respective reference categories, the significantly higher PR was evident for males, patients aged 41\u201364, White, with Medicare, median income &amp;lt;$25,000, all regions compared to Northeast, length of hospital stays, and conditions, including chronic pulmonary disease, diabetes, hypertension, obesity, and peripheral vascular disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study reveals a national overall and demographic-specific trend of increasing PAH with concurrent methamphetamine usage and associated factors. The findings may help to understand the current patterns and identify the vulnerable sociodemographic cohorts for further research and to take appropriate policy measures.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1445193","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:33:56Z","timestamp":1730090036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study"],"prefix":"10.3389","volume":"11","author":[{"given":"Amanda","family":"Husein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolie","family":"Boullion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ismail","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diensn","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Tareq Ferdous","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Shenuarin","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopi K.","family":"Kolluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Mostafizur Rahman","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Goeders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Vanchiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Wayne","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Kevil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Alfrad Nobel","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2102334","DOI":"10.1183\/13993003.02334-2021","article-title":"The physiological basis of pulmonary arterial hypertension","volume":"59","author":"Naeije","year":"2022","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"924873","DOI":"10.3389\/fcvm.2022.924873","article-title":"An overview of circulating pulmonary arterial hypertension biomarkers","volume":"9","author":"Santos-Gomes","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e000137","DOI":"10.1136\/bmjmed-2022-000137","article-title":"Pathophysiology and new advances in pulmonary hypertension","volume":"2","author":"Bousseau","year":"2023","journal-title":"BMJ Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1183\/09059180.00003313","article-title":"Drug-induced pulmonary arterial hypertension: a recent outbreak","volume":"22","author":"Montani","year":"2013","journal-title":"Eur Respir Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.medcli.2022.01.003","article-title":"Hipertensi\u00f3n arterial pulmonar","volume":"158","author":"Luna-Lopez","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1513\/AnnalsATS.202007-774OC","article-title":"Clinical differences and outcomes between methamphetamine-associated and idiopathic pulmonary arterial hypertension in the Pulmonary Hypertension Association Registry","volume":"18","author":"Kolaitis","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-023-01862-z","article-title":"Novel drugs for the treatment of pulmonary arterial hypertension: where are we going?","volume":"83","author":"Alamri","year":"2023","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"L967","DOI":"10.1152\/ajplung.00553.2017","article-title":"Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists","volume":"314","author":"Orcholski","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001917","article-title":"Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH biobank)","volume":"10","author":"Charoenpong","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1412867","DOI":"10.3389\/fcvm.2024.1412867","article-title":"Trends in peripheral artery disease and critical limb ischemia hospitalizations among cocaine and methamphetamine users in the United States: a nationwide study","volume":"11","author":"Ali","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100840","DOI":"10.1016\/j.jacadv.2024.100840","article-title":"Cardiomyopathy-associated hospital admissions among methamphetamine users: geographical and social disparities","volume":"3","author":"Al-Yafeai","year":"2024","journal-title":"JACC Adv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.redox.2022.102523","article-title":"Mitochondrial dysfunction and autophagy activation are associated with cardiomyopathy developed by extended methamphetamine self-administration in rats","volume":"58","author":"Abdullah","year":"2022","journal-title":"Redox Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100435","DOI":"10.1016\/j.abrep.2022.100435","article-title":"Early onset cardiovascular disease related to methamphetamine use is most striking in individuals under 30: a retrospective chart review","volume":"15","author":"Batra","year":"2022","journal-title":"Addict Behav Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.201705-0943OC","article-title":"Features and outcomes of methamphetamine-associated pulmonary arterial hypertension","volume":"197","author":"Zamanian","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e018370","DOI":"10.1161\/JAHA.120.018370","article-title":"Methamphetamine-associated heart failure hospitalizations across the United States: geographic and social disparities","volume":"10","author":"Dickson","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.phrs.2017.03.009","article-title":"Methamphetamine: effects on the brain, gut and immune system","volume":"120","author":"Prakash","year":"2017","journal-title":"Pharmacol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"115524","DOI":"10.1016\/j.psychres.2023","article-title":"Social-geographic disparities in suicidal ideations among methamphetamine users in the USA","volume":"329","author":"Xing","year":"2023","journal-title":"Psychiatry Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MCP.0000000000000513","article-title":"Methamphetamine and the risk of pulmonary arterial hypertension","volume":"24","author":"Ramirez","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"B22","volume-title":"Methamphetamine Response Act of 2021","year":"2022"},{"key":"B23","volume-title":"Plan to address methamphetamine supply, use, and consequences","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14688","article-title":"Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction","volume":"1508","author":"Jones","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.su7102a1","article-title":"Mental health surveillance among children\u2014United States, 2013\u20132019","volume":"71","author":"Bitsko","year":"2022","journal-title":"MMWR Suppl"},{"key":"B27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/YCO.0000000000000168","article-title":"Global patterns of methamphetamine use","volume":"28","author":"Chomchai","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1187\/cbe.13-04-0082","article-title":"The other half of the story: effect size analysis in quantitative research","volume":"12","author":"Maher","year":"2013","journal-title":"CBE Life Sci Educ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e003846","DOI":"10.1161\/CIRCOUTCOMES.117.003846","article-title":"With great power comes great responsibility: big data research from the National Inpatient Sample","volume":"10","author":"Khera","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e003226","DOI":"10.1161\/CIRCHEARTFAILURE.116.003226","article-title":"Variation in hospital use and outcomes associated with pulmonary artery catheterization in heart failure in the United States","volume":"9","author":"Khera","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2105\/AJPH.2019.305527","article-title":"Resurgent methamphetamine use at treatment admission in the United States, 2008\u20132017","volume":"110","author":"Jones","year":"2020","journal-title":"Am J Public Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"106478","DOI":"10.1016\/j.addbeh.2020.106478","article-title":"Historical trends of admitted patients by selected substances and their significant patient\u2019s level factors","volume":"109","author":"Mazumder","year":"2020","journal-title":"Addict Behav"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.jacc.2023.03.382","article-title":"Disparities in prevalence and trend of methamphetamine-associated cardiomyopathy in the United States","volume":"81","author":"Bhuiyan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","article-title":"Pulmonary arterial hypertension: diagnosis, treatment, and novel advances","volume":"203","author":"Maron","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.37765\/ajmc.2021.88609","article-title":"Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients","volume":"27","author":"Levine","year":"2021","journal-title":"Am J Manag Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s11606-021-06910-6","article-title":"Multimorbidity among US adults who use methamphetamine, 2015\u20132019","volume":"37","author":"Han","year":"2022","journal-title":"J Gen Intern Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"108089","DOI":"10.1016\/j.drugalcdep.2020.108089","article-title":"Trends in characteristics of individuals who use methamphetamine in the United States, 2015\u20132018","volume":"213","author":"Palamar","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"B38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/bph.12281","article-title":"Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response","volume":"171","author":"Mair","year":"2014","journal-title":"Br J Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5603\/CJ.a2018.0096","article-title":"Pulmonary arterial hypertension in the elderly: clinical perspectives","volume":"27","author":"Rothbard","year":"2020","journal-title":"Cardiol J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s10067-022-06446-y","article-title":"Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment","volume":"42","author":"Cansu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"108921","DOI":"10.1016\/j.drugalcdep.2021.108921","article-title":"Methamphetamine use among American Indians and Alaska natives in the United States","volume":"227","author":"Coughlin","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2334923","DOI":"10.1001\/jamanetworkopen.2023.34923","article-title":"Cardiovascular disease burden and outcomes among American Indian and Alaska native medicare beneficiaries","volume":"6","author":"Eberly","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2045894019894534","DOI":"10.1177\/2045894019894534","article-title":"High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude","volume":"10","author":"Dubroff","year":"2020","journal-title":"Pulm Circ"},{"key":"B44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev.publhealth.012809.103600","article-title":"The methamphetamine problem in the United States","volume":"31","author":"Gonzales","year":"2010","journal-title":"Annu Rev Public Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/00000441-199704000-00002","article-title":"Hypertension-related morbidity and mortality in the southeastern United States","volume":"313","author":"Hall","year":"1997","journal-title":"Am J Med Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","article-title":"Neurobiology, clinical presentation, and treatment of methamphetamine use disorder","volume":"77","author":"Paulus","year":"2020","journal-title":"JAMA Psychiatry"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1445193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:33:58Z","timestamp":1730090038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1445193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":46,"alternative-id":["10.3389\/fcvm.2024.1445193"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1445193","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"1445193"}}